Design Therapeutics DSGN
$9.02 −$0.30 (-3.22%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.02 0.00%
Open$9.33
Prev close$9.32
Day range$8.96 – $9.57
Volume281.9K
Market cap$577.61M
P/E (TTM)–
Dividend yield–
DSGN Stock News
Headlines matching Design Therapeutics or the DSGN ticker, most recent first.
- Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22
- Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21
- Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $21 Positive
- Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20
- RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 Positive
- Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22 Positive
- Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 Positive
- RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $14 Positive
- Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $15
- Jefferies Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $15
- Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $18
- RBC Capital Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $14
- Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC)
- Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20
- RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Cuts Target Price to $19 Negative
No comments yet — be the first to weigh in on DSGN.
Sign in to join the discussion.